Sander S Florman, MD

Clinical Focus

• Chronic Renal Failure
• Cirrhosis
• Hepatitis B
• Hepatitis C
• Kidney Failure
• Kidney Transplant
• Liver Cancer
• Liver Transplant

• Chronic Renal Failure
• Cirrhosis
• Hepatitis B
• Hepatitis C
• Kidney Failure
• Kidney Transplant
• Liver Cancer
• Liver Transplant

Locations

Recanati/Miller Transplantation Institute

5 East 98th Street, 12th Floor, New York, NY, 10029

212-241-8035

Insurance Information

Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Publications

Scopus h-index:43

Article:191

Review Article:13

Comment/Debate:3

Letter:4

Editorial:4

Chapter:4

Recent Artifacts

• DCD Hepatitis C Virus-positive Donor Livers Can Achieve Favorable Outcomes with Liver Transplantation and Are Underutilized
• State of pediatric liver transplantation in the United States and achieving zero wait list mortality with ideal outcomes: A statement from the Starzl Network for Excellence in Pediatric Transplant Surgeon's Working Group
• Enhanced recovery for liver transplantation: recommendations from the 2022 International Liver Transplantation Society consensus conference
• Outcomes in liver transplant recipients with nonalcoholic fatty liver disease-related HCC: Results from the US multicenter HCC transplant consortium
• Early Liver Transplantation for Severe Alcohol-Associated Hepatitis and a History of Prior Liver Decompensation
• Low-dose aspirin confers protection against acute cellular allograft rejection after primary liver transplantation
• Role of time from transplantation to biopsy in histologic ABMR: A single center report
• The effect of induction immunosuppression for kidney transplant on the latent HIV reservoir
• Optimal surgical workup to ensure safe recovery of the donor after living liver donation – A systematic review of the literature and expert panel recommendations
• The role of T-tubes and abdominal drains on short-term outcomes in liver transplantation – A systematic review of the literature and expert panel recommendations

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Florman during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.